Next Article in Journal
Exercise for People with Cancer: A Clinical Practice Guideline
Previous Article in Journal
Does Adjuvant Radiation Therapy Benefit Women with Small Mammography-Detected Breast Cancers?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 24
Issue 1
10.3747/co.24.3470
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma

by
D. MacDonald
1,*,
T. Crosbie
2,
A. Christofides
3,
W. Assaily
4 and
J. Wiernikowski
5
1
Division of Hematology, Dalhousie University, and QEII Health Sciences Centre, Halifax, NS, Canada
2
The Ottawa Hospital, Ottawa, ON, Canada
3
Impact Medicom Inc., Toronto, ON, Canada
4
Hoffmann–La Roche, Mississauga, ON, Canada
5
The Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(1), 33-39; https://doi.org/10.3747/co.24.3470
Submission received: 8 November 2016 / Revised: 6 December 2016 / Accepted: 5 January 2017 / Published: 1 February 2017

Abstract

Rituximab is widely used for the treatment of non-Hodgkin lymphoma, being a key component in most therapeutic regimens. Administration of the intravenous (IV) formulation is lengthy and places a significant burden on health care resources and patient quality of life. A subcutaneous (sc) formulation that provides a fixed dose of rituximab is being examined in a number of studies. Results indicate that the pharmacokinetics are noninferior and response rates are comparable to those obtained with the IV formulation. Moreover, the sc formulation is preferred by patients and health care providers and reduces administration and chair time. Additional advantages include a lesser potential for dosing errors, shorter preparation time, reduced drug wastage, and fewer infusion-related reactions. Despite the success of the sc formulation, correct administration is needed to reduce administration-related reactions. By using a careful procedure, the sc formulation can be given safely and effectively, potentially reducing the burden on health care resources and improving quality of life for patients.
Keywords: rituximab (subcutaneous); lymphoma; non-Hodgkin lymphoma rituximab (subcutaneous); lymphoma; non-Hodgkin lymphoma

Share and Cite

MDPI and ACS Style

MacDonald, D.; Crosbie, T.; Christofides, A.; Assaily, W.; Wiernikowski, J. A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma. Curr. Oncol. 2017, 24, 33-39. https://doi.org/10.3747/co.24.3470

AMA Style

MacDonald D, Crosbie T, Christofides A, Assaily W, Wiernikowski J. A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma. Current Oncology. 2017; 24(1):33-39. https://doi.org/10.3747/co.24.3470

Chicago/Turabian Style

MacDonald, D., T. Crosbie, A. Christofides, W. Assaily, and J. Wiernikowski. 2017. "A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma" Current Oncology 24, no. 1: 33-39. https://doi.org/10.3747/co.24.3470

APA Style

MacDonald, D., Crosbie, T., Christofides, A., Assaily, W., & Wiernikowski, J. (2017). A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma. Current Oncology, 24(1), 33-39. https://doi.org/10.3747/co.24.3470

Article Metrics

Back to TopTop